Drug intelligence / Profile preview

LMB-7

Development stage
Phase 1
Lead developer
National Cancer Institute
Modality
Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics
Administration
Intrathecal
01

Overview

LMB-7 is a single-chain immunotoxin constructed from the murine monoclonal antibody B3 and a truncated form of Pseudomonas exotoxin (PE38). It targets a carbohydrate epitope (LeY antigen) found on solid tumors that frequently invade the intrathecal space and cause neoplastic meningitis. The immunotoxin works by binding to cancer cells, becoming internalized, and delivering the toxin to the cytosol where it inhibits protein synthesis by inactivating eukaryotic elongation factor 2 (eEF2), ultimately leading to cell death. LMB-7 showed significant efficacy in preclinical rat models of carcinomatous meningitis but demonstrated unexpectedly low activity in subsequent clinical trials.

Other names
LMB-7 immunotoxinLMB7 immunotoxinLMB 7 immunotoxin
02

Targets

EEF2 (Eukaryotic elongation factor 2)LeY (Lewis Y antigen)

Beyond the preview

Go deeper on LMB-7.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on LMB-7.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call